The Obesity Wars of 2026 continue: Novo's Miss, Lilly's Supremacy, and the Quality of Weight Loss Pivot Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial The Lancet 5 GLP 1 trends to expect in 2026: Expanded uses, oral options, and more AOL cagrisema is one of the most #potent #weightloss medication developed till date! Cagrisema on an average causes 9% additional weight loss over #semaglutide 2.4mg week! Cagrisema is a fixed dose combination of semaglutide 2.4mg + # Nature: Dozens of new obesity drugs are coming: